Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

239 results
Display

Signature of arylacetamide deacetylase expression is associated with prognosis and immune infiltration in ovarian cancer

Feng J, He H

Objective The role of the protein-coding gene arylacetamide deacetylase (AADAC) in the prognostication of ovarian cancer remains uncertain. We aimed to identify and validate its prognostic value using integrated bioinformatics analyses. Methods Gene...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer

Angeles MA, Cabarrou B, Gil-Moreno A, Pérez-Benavente A, Spagnolo E, Rychlik A, Martínez-Gómez C, Guyon F, Zapardiel I, Querleu D, Illac C, Migliorelli F, Bétrian S, Ferron G, Hernández A, Martinez A

Objective We sought to evaluate the impact on survival of tumor burden and surgical complexity in relation to the number of cycles of neoadjuvant chemotherapy (NACT) in patients with advanced ovarian...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Adnexal Masses: Clinical Application of Multiparametric MR Imaging & O-RADS MRI

Eom SY, Rha SE

Incidental adnexal masses considered indeterminate for malignancy are commonly observed on ultrasonography. Multiparametric MRI is the imaging modality of choice for the evaluation of sonographically indeterminate adnexal masses. Conventional MRI...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry

Ha HI, Chang HK, Park SJ, Lim J, Won YJ, Lim MC

Objective The three major gynecologic cancers are cervical, endometrial, and ovarian cancer. This study aimed to describe the 19-year trends and survival rates in cervical, endometrial, and ovarian cancer in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of metformin on survival outcome in ovarian cancer: a nationwide population-based cohort study

Park JY, Lim MC, Baek MH, Park YH, Kim S

Objective Investigation of new drugs (INDs) is a tremendously inefficient process in terms of time and cost. Drug repositioning is another method used to investigate potential new agents in well-known drugs....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells

Cho Hy, Kim YB, Park Wh, No JH

Purpose This study aimed to evaluate anticancer effects of combination treatment with poly(ADP-ribose) polymerase (PARP) and checkpoint kinase 1 (Chk1) inhibitors in BRCA wild-type ovarian cancer. PARP inhibitors can function...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Umbilical Metastasis (Sister Mary Joseph’s Nodule) from Mucinous Ovarian Carcinoma

Kang MJ, Seo JM, Yun SY, Lee JH, Yu DS, Lee YB

  • KMID: 2517151
  • Korean J Dermatol.
  • 2021 Jun;59(5):413-415.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Assessment of different NEoplasias in the adneXa model for differentiation of benign and malignant adnexal masses in Korean women

Nam G, Lee SR, Jeong K, Kim SH, Moon HS, Chae HD

Objective Ultrasonographic differential diagnosis of ovarian tumors is important for appropriate management. We conducted study to compare the performance of the Assessment of Different NEoplasias in the adneXa (ADNEX) model...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Second Primary Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers after Breast Cancer Diagnosis: Korea Central Cancer Registry

Ha HI, Lee EG, Lim J, Jung SY, Chang YJ, Won YJ, Lim MC

Purpose A prior history of breast cancer is a risk factor for the subsequent development of primary peritoneal, epithelial ovarian, and fallopian tubal (POFT) cancers. This study aimed to estimate...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer

Tokunaga H, Mikami M, Nagase S, Kobayashi Y, Tabata T, Kaneuchi M, Satoh T, Hirashima Y, Matsumura N, Yokoyama Y, Kawana K, Kyo S, Aoki D, Katabuchi H

The fifth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was published in 2020. The guidelines...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)

Lee YJ, Lim MC, Kim BG, Ngoi NY, Choi CH, Park SY, Tan DS, Go Y, Lee JY

Background: The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore

Tan DS, Chan JJ, Hettle R, Ghosh W, Viswambaram A, Yu CC

Objective: To evaluate the cost-effectiveness of olaparib as a maintenance treatment versus routine surveillance (RS) in patients with BRCA mutated (BRCAm) advanced ovarian cancer (OC) following response to first-line platinum-based...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial

Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M, Takano M, Nishio S, Fujiwara H, Keiichi K, Kondo E, Sugiyama T, Tabata T

Objective: The standard dose for pegylated liposomal doxorubicin (PLD) is 50 mg/m2 every 4 weeks. While 40 mg/m2 has recently been used in clinical practice, evidence supporting this use remains...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Feasibility and safety of fertilitysparing surgery in epithelial ovarian cancer with dense adhesion: a longterm result from a single institution

Baek MH, Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT

Objective: We investigated the feasibility and safety of fertility-sparing surgery (FSS) in patients with epithelial ovarian cancer (EOC) with dense adhesions. Methods: Patients were divided into cases with and without dense...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reclassification of BRCA1 and BRCA2 variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers

Ha HI, Ryu JS, Shim H, Kong SY, Lim MC

Objective: We investigated the proportions of and reclassified BRCA1/2 variants of unknown significance (VUS) in Korean patients with epithelial ovarian, tubal, and primary peritoneal cancers. Methods: Data from 805 patients who...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea

Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS

Purpose This study aimed to present a single institutional experience with BRCA1/2 gene tests and the effects of pathogenic mutations in epithelial peritoneal, ovarian, and fallopian tube cancer (POFTC) on survival...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations

Ogasawara A, Hihara T, Shintani D, Yabuno A, Ikeda Y, Tai K, Fujiwara K, Watanabe K, Hasegawa K

Purpose Circulating tumor DNA (ctDNA) is an attractive source for liquid biopsy to understand molecular phenotypes of a tumor non-invasively, which is also expected to be both a diagnostic and prognostic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer

Chung YS, Kim HS, Lee JY, Kang WJ, Nam EJ, Kim S, Kim SW, Kim YT

Purpose The aim of this study was to evaluate the ability of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) after one cycle of neoadjuvant chemotherapy (NAC) to predict chemotherapy response before...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis

Chiyoda T, Sakurai M, Satoh T, Nagase S, Mikami M, Katabuchi H, Aoki D

Objective: To assess the effectiveness of lymphadenectomy at primary debulking surgery (PDS) on the survival of patients with epithelial ovarian cancer (EOC). Methods: We searched PubMed, Ichushi, and the Cochrane Library....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands

Burg L, Timmermans M, van der Aa M, Boll D, Rovers K, Hingh Id, Altena Av

Objective: Peritoneal metastases (PM) are a challenge in gynecological cancers, but its appearance has never been described in a population-based study. Therefore, we describe the incidence of PM and identify...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr